Image via citybiz — regional US deals
Last updated
Ratio Therapeutics: Capital Raising
Ratio Therapeutics closed a Series C funding round of $70M for radiopharmaceutical trials, led by existing investors Duquesne Family Office and Bristol Myers Squibb, with new investor participation.
Source: citybiz — regional US deals
The leadership read
Ratio Therapeutics's raise resets the leadership agenda more than the balance sheet. Capital into Biotech & Pharma buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across Americas.
Market context: The wider read — a Talent Market Index of 104.6 (Hot), down 1.9 month-on-month — shows Americas signal flow rising (+2.1pts).
Ratio Therapeutics: 2 signals in the last 90 days — above the Biotech & Pharma median of 1 across 24 tracked companies; 0.1% of MitchelLake's Americas signal flow; 2 tracked across 63 days.
MitchelLake in this thematic
Also at Ratio Therapeutics →
More signals across Biotech & Pharma
Capital Raising · Americas
BridgeBio →BridgeBio secured funding to support drug launch; United Airlines made an investment into the cell therapy space
Capital Raising · Americas
Twist Bioscience →Twist Bioscience filed an omnibus shelf registration and registered a $200M at-the-market (ATM) follow-on equity offering of common shares in June 2026.
Capital Raising · Americas
Sana Biotechnology, Inc. →Schedule 13G filing indicates potential significant ownership change or investment activity
Leadership Change · Americas
Flagship Pioneering →Flagship Pioneering, a scientific innovation engine, appointed two Executive Partners: Fidah Alsagoff (Head of Global Initiatives) and Maggie Sahlman (Head of Fundraising and Investor Relations).
Ma Activity · Americas
Bristol Myers Squibb →Bristol Myers Squibb is in merger talks with AstraZeneca regarding a potential $400 billion megadeal
Leadership Change · Americas
Teva Pharmaceuticals →Teva Pharmaceuticals CEO Richard Francis discusses Q2 earnings, drug pipeline, and the company's direct listing on NYSE. Signals leadership visibility and capital market transition.
Intelligence powered by Autonodal ↗